



MOREPEN

Date: 04/11/2015

To,

**National Stock Exchange of India
Limited**

Exchange Plaza,

Bandra Kurla Complex,

Bandra (East), Mumbai- 400 051

Tel No: (022) 26598100 - 8114

Fax No: (022) 26598120

BSE Limited

Floor 25, Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai- 400 001

Phones: 91-22-22721233/4

Fax: 91-22-2272 3121

Scrip Code: 500288

**Subject: Outcome of the meeting of the Board of Directors of the
Company held on 04th November, 2015**

Dear Sir,

This is to inform you that the Board of Directors of the Company, in their meeting held on 04th November, 2015, have inter-alia considered and approved the following matters:

1. The Un-audited Financial Results of the Company for the quarter and half year ended 30th September, 2015, along with Limited Review Report of the Auditors thereon (*Copy enclosed*).
2. Appointment of Ms. Archana Bhargava, as the Additional Director (Women Director) of the Company w.e.f. 04th November, 2015.

Kindly acknowledge the receipt and take it on your record.

Thanking you.

Yours faithfully,

For Morepen Laboratories Limited

(Thomas P. Joshua)

Company Secretary

Encl.: As Above

Morepen Laboratories Limited

Corp. Off.: 4th Floor, Antriksh Bhawan, 22 K.G. Marg, New Delhi -110 001, INDIA

Tel.: +91-11-23324443, E-mail: corporate@morepen.com Website: www.morepen.com

CIN NO. L24231HP1984PLC006028

Plant & Regd. Off.: Morepen Village, Malkumajra, Nalagarh Raod, Baddi, Distt. Solan (H.P.) 173 205

Tel.: +91-1795-266401-03, 244590, Fax : +91-1795-244591, E-mail: plants@morepen.com

CHARTERED ACCOUNTANTS

To

**The Board of Directors
Morepen Laboratories Limited
New Delhi**

Subject: Limited Review Report of un-audited financial results for the Quarter/ Half year ended 30th September 2015

1. We have reviewed the accompanying statement of unaudited financial results ("the statement") of **Morepen Laboratories Limited**, ("the company") for the quarter/ half year ended 30th September 2015 except for the disclosures regarding "Particulars of Equity Shareholding" and "Investors Complaints" which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Kamal Mahajan And Co.
Chartered Accountants
(Firm Regn No. 006855N)

Place : New Delhi
Date : 04.11.2015



Manik Bansal
(Manik Bansal)
Partner
Membership No.422936

Morepen Laboratories Limited Statement of Unaudited Financial Results For the Quarter ended 30th September, 2015							
Particulars		(Rs.in Lacs)					
		Standalone					
		Quarter Ended			Half Year Ended		Year Ended
		30.09.15	30.06.15	30.09.14	30.09.15	30.09.14	
		(Unaudited)			(Unaudited)		(Audited)
1(a)	Net Sales/Income from Operations (Net of Excise Duty)	10892.19	9927.56	8740.17	20819.75	17383.91	35459.13
(b)	Other Operating Income	407.93	428.35	377.98	836.28	875.60	1567.10
	Total Income from Operations (Net)	11300.12	10355.91	9118.15	21656.03	18259.51	37026.23
2	Expenditure						
a)	Cost of Material Consumed	4685.63	4310.45	3636.54	8996.08	7175.84	14522.67
b)	Purchase of stock - in - trade	2669.33	2329.76	2218.51	4999.09	4059.09	8322.11
c)	Changes in inventories of Finished goods, Work -in- progress, and Stock-in-trade	(417.43)	(224.26)	(45.37)	(641.69)	76.47	206.63
d)	Employee benefits expenses	1272.39	1215.77	1094.92	2488.16	2096.77	4352.37
e)	Depreciation and Amortisation	870.79	867.50	813.62	1738.29	1913.89	3859.49
f)	Power and Fuel	226.95	189.63	200.29	416.58	414.61	741.45
g)	Travelling Expenses	145.07	148.83	138.47	293.90	284.09	574.05
h)	Selling and Distribution Expenses	501.24	516.37	312.75	1017.61	752.67	1605.89
i)	Other Expenses	611.11	523.10	527.20	1134.21	950.21	2042.51
	Total Expenditure	10565.08	9877.15	8896.93	20442.23	17723.64	36227.17
3	Profit / (Loss) from Operations before Other Income, Finance Cost and Exceptional Items (1-2)	735.04	478.76	221.23	1213.80	535.88	799.06
4	Other Income /(Loss)	9.00	15.62	19.30	24.62	37.81	136.17
5	Profit / (Loss) from Ordinary activities before Finance Cost and Exceptional Items (3+4)	744.04	494.38	240.53	1238.42	573.69	935.23
6	Finance Cost	341.10	181.58	201.78	522.68	406.64	863.30
7	Profit / (Loss) from Ordinary activities after Finance Cost but before Exceptional Items (5-6)	402.94	312.80	38.75	715.74	167.05	71.93
8	Exceptional Items - Income/(Expense)	-	-	-	-	-	-
9	Profit / (Loss) from Ordinary Activities before Tax (7+8)	402.94	312.80	38.75	715.74	167.05	71.93
10	Tax Expense	80.62	62.58	7.75	143.20	33.42	13.70
11	Profit / (Loss) from Ordinary Activities after Tax (9-10)	322.32	250.22	31.00	572.54	133.63	58.23
12	Extraordinary Items-Income/(Expense)	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11+12)	322.32	250.22	31.00	572.54	133.63	58.23
14	Paid-up Equity Share Capital of Face Value of Rs.2/- each	8995.86	8995.86	8995.86	8995.86	8995.86	8995.86
15	Reserves excluding Revaluation reserve	-	-	-	-	-	10346.60
16	a) Earning Per Share before Extraordinary Items (in Rs.) *						
	Basic & Diluted	0.07	0.05	0.004	0.12	0.02	0.002
	b) Earning Per Share after Extraordinary Items (in Rs.) *						
	Basic & Diluted	0.07	0.05	0.004	0.12	0.02	0.002
A	PARTICULARS OF EQUITY SHAREHOLDING						
1	Public Shareholding						
	- Number of Shares	294454615	294454615	294454615	294454615	294454615	294454615
	- Percentage of shareholding	65.46%	65.46%	65.46%	65.46%	65.46%	65.46%
2	Promoters and Promoter Group Shareholding						
a)	Pledged / Encumbered						
	- Number of Shares	610000	610000	610000	610000	610000	610000
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.39%	0.39%	0.39%	0.39%	0.39%	0.39%
	- Percentage of shares (as a % of the total share capital of the company)						



*After considering dividend on preference shares.

Notes :

1. The above results have been reviewed by the Audit Committee and approved & taken on record by the Board of Directors at their meeting held on 4th November 2015. A Limited review of the same had been carried out by the statutory auditors.
2. The Company is exclusively engaged in the Pharmaceutical Business Segment.
3. Consolidated Income from Operations, Net Profit/ (Loss), EPS for the quarter ended 30th Sep, 2015 stands at Rs.11989.76 Lacs, Rs. 166.16 Lacs & Rs.0.03 respectively.
4. Statement of Assets and Liabilities:

Particulars	As at	
	30.09.2015	31.03.2015
	(Unaudited)	(Audited)
A EQUITY AND LIABILITIES		
1 Shareholders' Funds		
(a) Share Capital	20961.07	20961.07
(b) Reserves and Surplus	10919.14	10346.60
Shareholders' Funds	31880.21	31307.67
2 Non - Current Liabilities		
(a) Long term borrowings	5776.69	6222.42
(b) Other Long term liabilities	176.20	176.20
(c) Long term provisions	936.38	870.87
Non- current liabilities	6889.27	7269.49
3 Current Liabilities		
(a) Short term borrowings	92.53	223.32
(b) Trade Payables	7927.78	7855.20
(c) Other current liabilities	3398.55	3281.87
(d) Short term provisions	240.07	83.58
Current liabilities	11658.93	11443.97
TOTAL EQUITY AND LIABILITIES	50428.41	50021.13
B ASSETS		
1 Non Current Assets		
(a) Tangible Assets	22888.59	24342.53
(b) Intangible Assets	52.96	50.07
(c) Non - current Investments	11794.37	11794.22
(d) Long term loans and advances	3398.56	3393.47
Non- current assets	38134.48	39580.29
2 Current Assets		
(a) Inventories	4052.22	3536.31
(b) Trade receivables	6110.20	4844.52
(c) Cash and cash equivalents	547.85	859.85
(d) Short term loans and advances	1138.05	889.08
(e) Other current assets	445.61	311.08
Current assets	12293.93	10440.84
TOTAL ASSETS	50428.41	50021.13

Place : New Delhi

Date : 4th November, 2015



For and on behalf of the Board

(Sushil Suri)

Chairman & Managing Director